- Report
- March 2024
- 186 Pages
Global
From €3262EUR$3,374USD£2,802GBP
€3624EUR$3,749USD£3,113GBP
- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Drug Pipelines
- April 2024
- 120 Pages
Global
From €1934EUR$2,000USD£1,661GBP
- Report
- August 2022
- 120 Pages
Global
From €4592EUR$4,750USD£3,945GBP
- Report
- September 2021
- 40 Pages
China
From €2514EUR$2,600USD£2,159GBP
- Report
- May 2023
- 103 Pages
Global
From €3500EUR$3,878USD£3,112GBP
- Report
- April 2024
- 50 Pages
Global
From €2562EUR$2,650USD£2,201GBP
- Report
- February 2024
- 180 Pages
Global
From €3480EUR$3,600USD£2,990GBP
Zoledronic acid is a drug used to treat endocrine and metabolic disorders. It is a bisphosphonate, a type of drug that helps to reduce the activity of cells that break down bone. Zoledronic acid is used to treat conditions such as osteoporosis, Paget's disease, and hypercalcemia. It is also used to reduce the risk of fractures in people with osteoporosis. Zoledronic acid works by slowing down the activity of cells that break down bone, which helps to reduce bone loss and increase bone density.
Zoledronic acid is available in both oral and intravenous forms. The intravenous form is usually given as an infusion over a period of 15 minutes. The oral form is taken as a tablet once a day. Common side effects of zoledronic acid include nausea, vomiting, and diarrhea.
Companies in the zoledronic acid market include Novartis, Amgen, Merck, and Teva Pharmaceuticals. Show Less Read more